Egetis Therapeutics AB (publ)
EGTX
Rank in Stocks
#11899
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Share Price
$1.12
Last synced: 2026-11-12
Market Cap
$518.60M
Change (1 day)
-1.00%
Change (1 year)
60.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Egetis Therapeutics AB (publ) (EGTX)
Category
Healthcare
Operating Margin for Egetis Therapeutics AB (publ) (EGTX)
Operating Margin as of November 2026 TTM: -603.93%
According to Egetis Therapeutics AB (publ)'s latest financial reports, its current operating margin (TTM) is -603.93%. At the end of 2025 the company had an operating margin of -555.93%.
Operating Margin history for Egetis Therapeutics AB (publ) from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -603.93% | 8.63% |
| 2025 | -555.93% | -22.20% |
| 2024 | -714.53% | 26.71% |
| 2023 | -563.89% | -35.95% |
| 2022 | -880.44% | 218.61% |
| 2021 | -276.34% | -37.01% |
| 2020 | -438.73% | 443.25% |
| 2019 | -80.76% | -75.37% |
| 2018 | -327.94% | -49.43% |
| 2017 | -648.49% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | -142,557.35% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.75% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Egetis Therapeutics AB (publ)'s operating margin
What is Egetis Therapeutics AB (publ)'s operating margin?
Egetis Therapeutics AB (publ)'s operating margin is -603.93%, as of Nov 2026.
What was Egetis Therapeutics AB (publ)'s operating margin in 2025?
In 2025, Egetis Therapeutics AB (publ)'s operating margin was -555.93%, compared with -714.53% in 2024.
How has Egetis Therapeutics AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Egetis Therapeutics AB (publ)'s operating margin was highest in 2021 (-276.34%) and lowest in 2022 (-880.44%).
How does Egetis Therapeutics AB (publ)'s operating margin compare with similar companies?
Egetis Therapeutics AB (publ)'s operating margin (-603.93%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.